This partnership is publicized just shortly after the strategic collaboration that was reached between WCCT Global and the NIAID for influenza challenge research.
This agreement between DynPort and WCCT Global will be directed toward phase I support to demonstrate the safety of investigational therapeutic products being studied by the NIAID in order to provide data for appropriate human dosing in later phase development.
The types of therapeutic agents that will be investigated include potential medications again4st bacterial, parasitic, and fungal pathogens.
WCCT Global’s CEO Dr. Kenneth Kim stated, "WCCT Global was chosen as a strategic partner because of our influenza challenge capabilities and our excellent track record in the successful execution of phase I studies for anti-infective agents. We look forward to working with DynPort and the other partners in this exciting research venture."